Vantage logo

Finding the next Prevail

An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.

Vantage logo

First blood: Rubius approaches its big test

The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…